Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. Cullen, K., R., Amatya, P., Roback, M., G., Albott, C., S., Westlund Schreiner, M., Ren, Y., Eberly, L., E., Carstedt, P., Samikoglu, A., Gunlicks-Stoessel, M., Reigstad, K., Horek, N., Tye, S., J., Lim, K., O., & Klimes-Dougan, B. Journal of Child and Adolescent Psychopharmacology, Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA, 7, 2018.
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study [link]Website  abstract   bibtex   
Abstract Background: Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. Methods: Adolescents, 12–18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0.5 mg/kg) infusions over 2 weeks. Clinical response was defined as a 50% decrease in Children's Depression Rating Scale-Revised (CDRS-R); remission was CDRS-R score ≤28. Tolerability assessment included monitoring vital signs and dissociative symptoms using the Clinician-Administered Dissociative States Scale (CADSS). Results: Thirteen participants (mean age 16.9 years, range 14.5–18.8 years, eight biologically male) completed the protocol. Average decrease in CDRS-R was 42.5% (p = 0.0004). Five (38%) adolescents...
@article{
 title = {Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study},
 type = {article},
 year = {2018},
 identifiers = {[object Object]},
 pages = {cap.2018.0030},
 websites = {http://www.liebertpub.com/doi/10.1089/cap.2018.0030},
 month = {7},
 publisher = {Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA},
 day = {13},
 id = {73a458bc-0864-3f77-b8e8-49d56850b282},
 created = {2018-07-22T08:49:39.725Z},
 accessed = {2018-07-18},
 file_attached = {false},
 profile_id = {078d13e5-632a-3ebf-9e0e-51a0b2c2c66e},
 group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
 last_modified = {2019-10-25T16:37:14.481Z},
 tags = {CA,Disc:Psychopharmacology},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {false},
 hidden = {false},
 notes = {LB},
 private_publication = {false},
 abstract = {Abstract Background: Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. Methods: Adolescents, 12–18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0.5 mg/kg) infusions over 2 weeks. Clinical response was defined as a 50% decrease in Children's Depression Rating Scale-Revised (CDRS-R); remission was CDRS-R score ≤28. Tolerability assessment included monitoring vital signs and dissociative symptoms using the Clinician-Administered Dissociative States Scale (CADSS). Results: Thirteen participants (mean age 16.9 years, range 14.5–18.8 years, eight biologically male) completed the protocol. Average decrease in CDRS-R was 42.5% (p = 0.0004). Five (38%) adolescents...},
 bibtype = {article},
 author = {Cullen, Kathryn R. and Amatya, Palistha and Roback, Mark G. and Albott, Christina Sophia and Westlund Schreiner, Melinda and Ren, Yanan and Eberly, Lynn E. and Carstedt, Patricia and Samikoglu, Ali and Gunlicks-Stoessel, Meredith and Reigstad, Kristina and Horek, Nathan and Tye, Susanna J and Lim, Kelvin O. and Klimes-Dougan, Bonnie},
 journal = {Journal of Child and Adolescent Psychopharmacology}
}

Downloads: 0